Myriad Genetics, Inc. (0K3W.L)

18,80 -1,25 (-6,21%) In data: 05:12PM BST. Mercato aperto.

Myriad Genetics, Inc.

322 North 2200 West
Salt Lake City, UT 84116
United States
801 584 3600
https://www.myriad.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 2.700

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Paul J. Diaz	CEO, President & Director	1,88M	N/D	1962
Dr. Kevin Richard Haas Ph.D.	Chief Technology Officer	580,36k	N/D	1986
Mr. Mark S. Verratti	Chief Commercial Officer	794,85k	N/D	1968
Mr. Scott J. Leffler	Chief Financial Officer	N/D	N/D	1975
Mr. Samraat S. Raha	Chief Operating Officer	N/D	N/D	1973
Ms. Natalie Munk	Principal Accounting Officer	N/D	N/D	1981
Dr. Dale Muzzey Ph.D.	Chief Scientific Officer	N/D	N/D	1980
Mr. Matthew Scalo	Senior Vice President of Investor Relations	N/D	N/D	N/D
Mr. Glenn Farrell	Senior VP & Chief Marketing Officer	N/D	N/D	N/D
Ms. Shereen Solaiman	Chief People Officer	N/D	N/D	1973

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Governance aziendale

L'ISS Governance QualityScore di Myriad Genetics, Inc. al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 1; diritti degli azionisti: 5; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.